# Staci Martin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/staci-martin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,232 |
| Field | Neurofibromatosis and Schwannoma Cases |
| h-index | 43 |
| i10-index | 76 |
| Last Known Institution | Cancer Institute (WIA) |
| OpenAlex ID | https://openalex.org/A5048681548 |
| ORCID iD | 0000-0002-9342-4173 |
| Works | 125 |

## Researcher papers

- [CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy](https://scholariq.org/papers/cd22-targeted-car-t-cells-induce-remission-in-b-all-that-is-naive-or-resistant/)
- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas](https://scholariq.org/papers/activity-of-selumetinib-in-neurofibromatosis-type-1-related-plexiform/)
- [Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.](https://scholariq.org/papers/measurement-of-fatigue-in-cancer-patients-development-and-validation-of-the/)
- [CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial](https://scholariq.org/papers/cd4-cd8-t-cell-selection-affects-chimeric-antigen-receptor-car-t-cell-potency/)
- [A Multidimensional Measure of Fatigue for Use with Cancer Patients](https://scholariq.org/papers/a-multidimensional-measure-of-fatigue-for-use-with-cancer-patients/)
- [Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL](https://scholariq.org/papers/long-term-follow-up-of-cd19-car-t-cell-therapy-in-children-and-young-adults-with/)
- [CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR](https://scholariq.org/papers/cd19-22-car-t-cells-in-children-and-young-adults-with-b-all-phase-1-results-and/)
- [Management of neurofibromatosis type 1-associated plexiform neurofibromas](https://scholariq.org/papers/management-of-neurofibromatosis-type-1-associated-plexiform-neurofibromas/)
- [Functional outcome measures for NF1-associated optic pathway glioma clinical trials](https://scholariq.org/papers/functional-outcome-measures-for-nf1-associated-optic-pathway-glioma-clinical/)
- [A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib](https://scholariq.org/papers/a-mixed-methods-study-of-medication-adherence-in-adults-with-neurofibromatosis/)

## Researcher topics

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Meningioma and schwannoma management](https://scholariq.org/topics/meningioma-and-schwannoma-management/)
- [Tuberous Sclerosis Complex Research](https://scholariq.org/topics/tuberous-sclerosis-complex-research/)
- [Childhood Cancer Survivors' Quality of Life](https://scholariq.org/topics/childhood-cancer-survivors-quality-of-life/)

## Researcher university

- [Cancer Institute (WIA)](https://scholariq.org/institutions/cancer-institute-wia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.